Despite Washington’s move to tighten policy on pharmaceutical trade with a fresh threat of 100 per cent tariffs on generic drug imports, analysts say China’s pharmaceutical rise is now tariff-proof, making its ascent in the global supply chain look irreversible.US President Donald Trump announced plans on Tuesday to impose escalating tariffs on all generic drugs shipped to the country beginning in August 2028. Under the proposed schedule, tariffs would rise to 100 per cent within the first year and climb to 200 per cent thereafter.Trump said on social media that the tariff escalation was intended to “reshore generic pharmaceutical production into America”, adding that the measure would build on his administration’s “so successful” policy on patented, branded, or innovative drugs, which were already subject to tariffs as of earlier this year.However, analysts and industry experts said the proposed tariffs carried little weight for China as the plan was both economically impractical and targeted a segment where Beijing’s direct exposure is limited.“By moving generic manufacturing to the US, the cost will likely more than double, taking into account supply chain, manufacturing [and] waste management,” said Bruce Liu, senior partner at global consulting firm Simon-Kucher.“US patients would be the ones standing to lose,” Liu added.